drugset / Trial / NCT05653284
A Study of AK130 in Patients With Advanced Malignant Tumors
NaSingle-groupOpen-labelTreatment
Summary
A Phase I open label, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of AK130 (TIGIT/TGF-β bifunctional fusion protein) in patients with advanced malignant tumors.
Timeline
- Start
- 2023-02-09
- Primary completion
- 2023-12-12
- Completion
- 2024-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LUCORAFUSP ALFA | Protein / enzyme biologic | — | Intravenous |